157 related articles for article (PubMed ID: 31322992)
1. Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi.
Painschab MS; Kohler RE; Kasonkanji E; Zuze T; Kaimila B; Nyasosela R; Nyirenda R; Krysiak R; Gopal S
J Glob Oncol; 2019 Jul; 5():1-10. PubMed ID: 31322992
[TBL] [Abstract][Full Text] [Related]
2. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
[TBL] [Abstract][Full Text] [Related]
4. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
5. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
6. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
7. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma.
Best JH; Hornberger J; Proctor SJ; Omnes LF; Jost F
Value Health; 2005; 8(4):462-70. PubMed ID: 16091023
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
Johnston KM; Marra CA; Connors JM; Najafzadeh M; Sehn L; Peacock SJ
Value Health; 2010; 13(6):703-11. PubMed ID: 20561333
[TBL] [Abstract][Full Text] [Related]
10. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
11. Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia.
Costa S; Scott DW; Steidl C; Peacock SJ; Regier DA
Curr Oncol; 2019 Apr; 26(2):108-113. PubMed ID: 31043812
[TBL] [Abstract][Full Text] [Related]
12. Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.
Cher BP; Gan KY; Aziz MIA; Lin L; Hwang WYK; Poon LM; Ng K
J Med Econ; 2020 Nov; 23(11):1321-1329. PubMed ID: 32780608
[TBL] [Abstract][Full Text] [Related]
13. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
15. Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.
Wang HI; Smith A; Aas E; Roman E; Crouch S; Burton C; Patmore R
Eur J Health Econ; 2017 Mar; 18(2):255-267. PubMed ID: 26969332
[TBL] [Abstract][Full Text] [Related]
16. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
17. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors.
Telio D; Fernandes K; Ma C; Tsang R; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2012 May; 53(5):836-41. PubMed ID: 22136378
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands.
Groot MT; Lugtenburg PJ; Hornberger J; Huijgens PC; Uyl-de Groot CA
Eur J Haematol; 2005 Mar; 74(3):194-202. PubMed ID: 15693788
[TBL] [Abstract][Full Text] [Related]
20. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S; Tobinai K; Yi J; Crawford B
PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]